Atorvastatin and Clopidogrel

To the Editor:

I would like to comment on the recent editorial by Serebruany et al in which the study results by Lau et al are discussed. It is argued that these results, which are suggestive of a clinically relevant interaction between clopidogrel and atorvastatin, are in conflict with those published previously by Serebruany et al. According to the editorial, “. . .only 4 of 25 patients in the atorvastatin treated group did not exhibit sustained platelet inhibition. . .” From their original publication, however, it is clear that 25 is the total number of patients receiving any statin and that the number of patients receiving atorvastatin is 9. Other numbers cited in the editorial do not compare well with the original data either. The subgroup analyses of these data that were presented in the editorial were not presented in the original paper, which precludes the reader from assessing the statements made.

As these points are crucial to the argumentation made in the editorial, the apparent discrepancy between the cited data in the editorial and the original data warrants clarification.

Per Damkier, MD, PhD
Department KKA
Clinical Pharmacology
Odense University Hospital
DK-5000 Odense C, Denmark
pdamkier@health.sdu.dk

Response

Dr Damkier correctly notes a discrepancy between the cited data in the editorial and the original PRONTO data and requests clarification.

The data cited in the editorial are correct but refer to our preliminary analyses of INTERACTION (abstract accepted for presentation at the European Society of Cardiology Meeting in Vienna, Austria, August 30 through September 3, 2003, and Serebruany et al.). The correct PRONTO data are as follows. Overall, 4 of 25 patients did not exhibit sustained platelet inhibition. The distribution by statin therapy was 2 of 9 for atorvastatin, 1 of 6 for fluvastatin, 1 of 4 for pravastatin, 0 of 3 for cerivastatin, 0 of 2 for lovastatin, and 0 of 1 for simvastatin.

We are grateful to Dr Damkier for drawing our attention to the inadvertent error in transcription that caused the discrepancy.

Victor L. Serebruany, MD, PhD
Sinai Thrombosis Center
Johns Hopkins University
Baltimore, Md

Steven R. Steinhubl, MD
University of North Carolina
Chapel Hill, NC

Charles H. Hennekens, MD, DrPH
University of Miami
Mount Sinai Medical Center-Miami Heart Institute
Miami, Fla

Atorvastatin and Clopidogrel
Per Damkier

Circulation. 2003;108:e96
doi: 10.1161/01.CIR.0000092030.47705.A5
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2003 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://circ.ahajournals.org/content/108/13/e96

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org/subscriptions/